Telix Pharmaceuticals (TLX AU) aims to raise at least US$100m in its US ADS listing. The bookrunners on the deal are Jefferies, Morgan Stanley, Truist Securities, and William Blair.
What is covered in the Full Insight:
Deal Background
Past Funding Deals
Recent Performance and Deal Impact
Upcoming Developments
Analysts' Views and Valuation
Boomeranged on Thu, 6 Jun 2024 14:45
Telix Pharmaceuticals has launched its bookbuild to raise US$200m from its US ADR listing. Pricing is scheduled for 13th Jun 2024, after market close. The shares have continued to trade higher, and are now 15.9% higher than when we first published our note on the deal.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.